Modality
Fusion Protein
MOA
VEGFi
Target
BCMA
Pathway
Checkpoint
NSCLC
Development Pipeline
Preclinical
~Jan 2010
→ ~Apr 2011
Phase 1
~Jul 2011
→ ~Oct 2012
Phase 2
~Jan 2013
→ ~Apr 2014
Phase 3
~Jul 2014
→ ~Oct 2015
NDA/BLA
~Jan 2016
→ ~Apr 2017
Approved
Jul 2017
→ Apr 2028
ApprovedCurrent
NCT08821682
852 pts·NSCLC
2023-09→2028-04·Completed
NCT08141886
1,569 pts·NSCLC
2017-07→2028-01·Active
2,421 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2028-01-171.8y awayPh3 Readout· NSCLC
2028-04-152.0y awayPh3 Readout· NSCLC
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Approved
Active
Approved
Complet…
Catalysts
Ph3 Readout
2028-01-17 · 1.8y away
NSCLC
Ph3 Readout
2028-04-15 · 2.0y away
NSCLC
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08821682 | Approved | NSCLC | Completed | 852 | VA |
| NCT08141886 | Approved | NSCLC | Active | 1569 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA |